Arthur Levin
Fortune : 686 697 $ au 31/05/2026
Fortune : 686 697 $ au 31/05/2026
Arthur A. Levin is currently an Independent Director at Stoke Therapeutics, Inc. since 2015 and a Member of the Supervisory Board at Amylon Therapeutics BV.
Formerly, Dr. Levin was Director & Strategic Leader at Avidity Biosciences, Inc. from 2013 to 2026, Director at Oligonucleotide Therapeutics Society, Inc., Senior Vice President-Development at Ionis Pharmaceuticals, Inc., Executive Vice President-Research & Development at miRagen Therapeutics, Inc. from 2012 to 2014, Research Leader at Hoffmann-La Roche, Inc., and Chief Development Officer & Vice President at RICC A. Education includes a doctorate from Rochester Christian University and an undergraduate degree from Muhlenberg College conferred in 1975.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
STOKE THERAPEUTICS, INC. 0,04 % | 03/06/2026 | 22 216 ( 0,04 % ) | 686 697 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| STOKE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/09/2015 |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapies for central nervous system | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 23/02/2023 |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops microRNA-based therapeutics for cardiovascular and muscle diseases | Directeur Technique/Scientifique/R&D | 01/01/2014 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Directeur/Membre du Conseil | - |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
Rochester Christian University
Rochester Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops microRNA-based therapeutics for cardiovascular and muscle diseases | Health Technology |
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that provides research and development, administrative & investment services | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Muhlenberg College
Muhlenberg College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Develops therapies for central nervous system | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national